Bolt Biotherapeutics Inc   (BOLT)
Other Ticker:  
Price: $1.2000 $0.07 6.195%
Day's High: $1.24 Week Perf: 11.11 %
Day's Low: $ 1.11 30 Day Perf: -1.64 %
Volume (M): 273 52 Wk High: $ 2.03
Volume (M$): $ 327 52 Wk Avg: $1.26
Open: $1.13 52 Wk Low: $0.84

 Market Capitalization (Millions $) 45
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Bolt Biotherapeutics Inc
Bolt Biotherapeutics Inc is a biotechnology company focused on developing immune-stimulating therapies for cancer treatment. The company's proprietary Immune-Stimulating Antibody Conjugates (ISACs) aim to enhance the body's immune response to specifically target and kill cancer cells. Bolt Biotherapeutics' therapies utilize a unique approach that combines the specificity of monoclonal antibodies with the ability to activate the immune system. By leveraging this technology, the company aims to provide more effective and durable treatments for patients with various types of cancer.

   Company Address: 900 Chesapeake Redwood City 94063 CA
   Company Phone Number: 665-9295   Stock Exchange / Ticker: NASDAQ BOLT
   BOLT is expected to report next financial results on March 28, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Bolt Biotherapeutics Enters Phase 2 Trial with BDC-1001, Potentially Revolutionizing HER2-Positive Breast Cancer Treatment, Amidst Revenue Growth

Published Tue, Dec 5 2023 12:00 PM UTC

Bolt Biotherapeutics Initiates Phase 2 Study for BDC-1001 in HER2-Positive Breast Cancer Patients Previously Treated with Enhertu
REDWOOD CITY, Calif., Dec. 05, 2023 - Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a leading biopharmaceutical company specializing in novel immunotherapies for cancer treatment, has announced the enrollment of the first patient in their Ph...

Bolt Biotherapeutics Inc

Bolt Biotherapeutics Inc Demonstrates Robust Growth and Sustained Progress Throughout Q3 2023

In the third quarter of 2023, Bolt Biotherapeutics Inc, a major player in the Major Pharmaceutical Preparations industry, showed signs of improvement despite a challenging environment for the industry as a whole. The company reported a decreased loss per share of $-0.43, compared to $-0.58 in the same quarter the previous year. Additionally, income per share improved from $-0.48 in the previous quarter.
One of the key highlights for Bolt Biotherapeutics Inc in the third quarter was a considerable increase in revenue. The company's revenue rose by 19.697% to $2.53 million from $2.11 million in the same quarter a year earlier. Sequentially, the revenue surged by an impressive 76.413% from $1.43 million in the previous quarter.

Bolt Biotherapeutics Inc

Top-line Growth restrained at the Company from April to June 30, 2023 Even as Bolt Biotherapeutics Narrows Losses Per Share in Recent Fiscal Quarter

The financial results of Bolt Biotherapeutics Inc. for the most recent fiscal period unveil a mixed bag of performances. While the company reported narrowed losses per share compared to the previous year, it witnessed an increase in deficit from the preceding reporting period. This article will interpret the financial results and ponder over their potential impact on the company's future prospects.
1. Improved Losses per Share:
In the most recent fiscal period, Bolt Biotherapeutics Inc. managed to reduce its losses per share to $-0.48 from $-0.61 in the prior year. This signifies a positive trend for the company, indicating a potential improvement in its financial health.

Bolt Biotherapeutics Inc

Bolt Biotherapeutics Inc Bleeds Money, Leaving Investors Concerned Despite Marginal Improvement in Earnings

Bolt Biotherapeutics Inc, a clinical-stage immuno-oncology company, recently reported its financial results for the fiscal first quarter of 2023. While the company managed to decrease its loss per share compared to the year prior, there still remains a significant deficit in their reported finances.
Furthermore, the slight improvement in earnings per share seems to be quite trivial compared to the overall situation of the company. The fact of the matter is that Bolt Biotherapeutics Inc is still haemorrhaging money, with a net deficit of $-16.980 million in the fiscal first quarter of 2023. This is a significant amount of money to lose, which is worrying for the company's long-term viability.


Bolt Biotherapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com